A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy.
Dermatol Online J
; 23(8)2017 Aug 15.
Article
em En
| MEDLINE
| ID: mdl-29469753
ABSTRACT
Nivolumab, a monoclonal antibody against the programmed cell death protein 1 (PD-1), has shown promising results in patients with advanced malignancies, including melanoma, lung cancer, and renal cancer. Immune-related adverse events (irAEs) have been reported, including both organ-specific toxicities and skin toxicities. Herein, we report a case of predominantly palmoplantar psoriasis with severe nail involvement, psoriatic arthritis, and autoimmune hypothyroidism after receiving nivolumab treatment for lung cancer. We also summarize the case reports that have been published previously. The knowledge of these irAEs in patients undergoing anti-PD1 therapy is important since it will enable earlier recognition and appropriate management, with the aim of maintaining effective dose without disruption.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Tireoidite Autoimune
/
Artrite Psoriásica
/
Carcinoma Pulmonar de Células não Pequenas
/
Doença de Hashimoto
/
Neoplasias Pulmonares
/
Anticorpos Monoclonais
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Espanha